Syk Interacts with and Phosphorylates Nucleolin To Stabilize Bcl-x_L mRNA and Promote Cell Survival

REFERENCES

• Geahlen RL. 2009. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim. Biophys. Acta 1793:1115–1127. http://dx.doi.org/10.1016/j.bbamcr.2009.03.004.
   PubMed Web of Science ®Google Scholar
• Mócsai A, Ruland J, Tybulewicz VL. 2010. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat. Rev. Immunol. 10:387–402. http://dx.doi.org/10.1038/nri2765.
   PubMed Web of Science ®Google Scholar
• Rinaldi A, Kwee I, Taborelli M, Largo C, Uccella S, Martin V, Poretti G, Gaidano G, Calabrese G, Martinelli G, Baldini L, Pruneri G, Capella C, Zucca E, Cotter FE, Cigudosa JC, Catapano CV, Tibiletti MG, Bertoni F. 2006. Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. Br. J. Haematol. 132:303–316. http://dx.doi.org/10.1111/j.1365-2141.2005.05883.x.
   PubMed Web of Science ®Google Scholar
• Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA. 2008. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 111:2230–2237. http://dx.doi.org/10.1182/blood-2007-07-100115.
   PubMed Web of Science ®Google Scholar
• Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC, Potter TA, Refaeli Y. 2009. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood 113:2508–2516. http://dx.doi.org/10.1182/blood-2008-05-158618.
   PubMed Web of Science ®Google Scholar
• Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholomé K, Burger M, Chevalier N, Vallat L, Timmer J, Gribben JG, Jumaa H, Veelken H, Dierks C, Zirlik K. 2009. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 69:5424–5432. http://dx.doi.org/10.1158/0008-5472.CAN-08-4252.
   PubMed Web of Science ®Google Scholar
• Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, Cassuto JP, Ticchioni M, Deckert M. 2009. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCδ and proteasome-dependent regulation of Mcl-1 expression. Oncogene 28:3261–3273. http://dx.doi.org/10.1038/onc.2009.179.
   PubMed Web of Science ®Google Scholar
• Gobessi S, Laurenti L, Longo PG, Carsetti L, Bemo V, Sica S, Leone G, Effremov DG. 2009. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells. Leukemia 23:686–697. http://dx.doi.org/10.1038/leu.2008.346.
   PubMed Web of Science ®Google Scholar
• Uckun FM, Ek RO, Jan ST, Chen CL, Qazi S. 2010. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic. Br. J. Haematol. 149:508–517. http://dx.doi.org/10.1111/j.1365-2141.2010.08106.x.
   PubMed Web of Science ®Google Scholar
• Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL. 2011. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 118:6342–6352. http://dx.doi.org/10.1182/blood-2011-02-333773.
   PubMed Web of Science ®Google Scholar
• Hatton O, Lambert SL, Phillips LK, Vaysberg M, Natkunam Y, Esquivel CO, Krams SM, Martinez OM. 2013. Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder. Am. J. Transplant. 13:883–890. http://dx.doi.org/10.1111/ajt.12137.
   PubMedGoogle Scholar
• Balaian L, Ball ED. 2006. Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia 20:2093–2101. http://dx.doi.org/10.1038/sj.leu.2404437.
   PubMed Web of Science ®Google Scholar
• Hahn CK, Berchuck JE, Ross KN, Kakoza RM, Clauser K, Schinzel AC, Ross L, Galinsky I, Davis TN, Silver SJ, Root DE, Stone RM, DeAngelo DJ, Carroll M, Hahn WC, Carr SA, Golub TR, Kung AL, Stegmaier K. 2009. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell 16:281–294. http://dx.doi.org/10.1016/j.ccr.2009.08.018.
   PubMed Web of Science ®Google Scholar
• Kuno Y, Abe A, Emi N, Iida M, Yokozawa T, Towatari M, Tanimoto M, Saito H. 2001. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 97:1050–1055. http://dx.doi.org/10.1182/blood.V97.4.1050.
   PubMed Web of Science ®Google Scholar
• Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. 2006. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. Leukemia 20:313–318. http://dx.doi.org/10.1038/sj.leu.2404045.
   PubMed Web of Science ®Google Scholar
• Feldman AL, Sun DX, Law ME, Novak AJ, Attygalle AD, Thorland EC, Fink SR, Vrana JA, Caron BL, Morice WG, Remstein ED, Grogg KL, Kurtin PJ, Macon WR, Dogan A. 2008. Overexpression of Syk tyrosine kinase in peripheral T-cell lymphomas. Leukemia 22:1139–1143. http://dx.doi.org/10.1038/leu.2008.77.
   PubMed Web of Science ®Google Scholar
• Singh A, Greninger P, Rhodes D, Koopman L, Violette S, Bardeesy N, Settleman J. 2009. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell 15:489–500. http://dx.doi.org/10.1016/j.ccr.2009.03.022.
   PubMed Web of Science ®Google Scholar
• Zhang J, Benavente CA, McEvoy J, Flores-Otero J, Ding L, Chen X, Ulyanov A, Wu G, Wilson M, Wang J, Brennan R, Rusch M, Manning AL, Ma J, Easton J, Shurtleff S, Mullighan C, Pounds S, Mukatira S, Gupta P, Neale G, Zhao D, Lu C, Fulton RS, Fulton LL, Hong X, Dooling DJ, Ochoa K, Naeve C, Dyson NJ, Mardis ER, Bahrami A, Ellison D, Wilson RK, Downing JR, Dyer MA. 2012. A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481:329–334. http://dx.doi.org/10.1038/nature10733.
   PubMed Web of Science ®Google Scholar
• Prinos P, Garneau D, Lucier J-F, Gendron D, Couture S, Boivin M, Brosseau J-P, Lapointe E, Thibault P, Durand M, Tremblay K, Gervais-Bird J, Nwilati H, Klinck R, Chabot B, Perreault J-P, Wellinger RJ, Elela SA. 2011. Alternative splicing of SYK regulates mitosis and cell survival. Nat. Struct. Mol. Biol. 18:673–680. http://dx.doi.org/10.1038/nsmb.2040.
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, LaCasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA. 2010. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 115:2578–2585. http://dx.doi.org/10.1182/blood-2009-08-236471.
   PubMed Web of Science ®Google Scholar
• Herman SEM, Barr PM, McAuley EM, Liu D, Wiestner A, Friedberg JW. 2013. Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia 27:1769–1773. http://dx.doi.org/10.1038/leu.2013.37.
   PubMed Web of Science ®Google Scholar
• Geahlen RL. 2014. Getting Syk: spleen tyrosine kinase as a therapeutic target. Trends Pharmacol. Sci. 35:414–422. http://dx.doi.org/10.1016/j.tips.2014.05.007.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. 2011. Hallmarks of cancer: the next generation. Cell 144:646–674. http://dx.doi.org/10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• Youle RJ, Strasser A. 2008. The BCL-2 protein family: opposing activities that mediate cell death. Nat. Rev. Mol. Cell Biol. 9:47–59. http://dx.doi.org/10.1038/nrm2308.
   PubMed Web of Science ®Google Scholar
• Boise LH, González-García M, Postema CE, Ding L, Lindsten T, Turka LA, Mao X, Nuñez G, Thompson CB. 1993. bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 74:597–608. http://dx.doi.org/10.1016/0092-8674(93)90508-N.
   PubMed Web of Science ®Google Scholar
• Zhang X, Shrikhande U, Alicie BM, Zhou Q, Geahlen RL. 2009. Role of the protein tyrosine kinase Syk in regulating cell-cell adhesion and motility in breast cancer cells. Mol. Cancer Res. 7:634–644. http://dx.doi.org/10.1158/1541-7786.MCR-08-0371.
   PubMed Web of Science ®Google Scholar
• Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. 1995. Bcl-XL and Bcl-2 repress a common pathway of cell death. J. Exp. Med. 182:821–828. http://dx.doi.org/10.1084/jem.182.3.821.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Geahlen RL. 2009. The protein-tyrosine kinase Syk interacts with TRAF-interacting protein TRIP in breast epithelial cells. Oncogene 28:1348–1356. http://dx.doi.org/10.1038/onc.2008.493.
   PubMedGoogle Scholar
• Ramos-Vara JA, Miller MA, Valli VE. 2007. Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20. Vet. Pathol. 44:875–884. http://dx.doi.org/10.1354/vp.44-6-875.
   PubMedGoogle Scholar
• Coopman PJP, Do MTH, Barth M, Bowden ET, Hayes AJ, Basyuk E, Blancato JK, Vezza PR, McLeskey SW, Mangeat PH, Mueller SC. 2000. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature 406:742–747. http://dx.doi.org/10.1038/35021086.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. 1993. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 53:3976–3985.
   PubMed Web of Science ®Google Scholar
• Olapade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, Recant WM. 1997. Overexpression of Bcl-x protein in primary breast cancer is associated with high grade and nodal metastases. Cancer J. Sci. Am. 3:230–237.
   PubMedGoogle Scholar
• Fiebig AA, Zhu W, Hollerbach C, Leber B, Andrews DW. 2006. Bcl-XL is qualitatively different from and ten times more effective than Bcl-2 when expressed in a breast cancer cell line. BMC Cancer 6:213. http://dx.doi.org/10.1186/1471-2407-6-213.
   PubMed Web of Science ®Google Scholar
• Ito D, Frantz AM, Williams C, Thomas R, Burnett RC, Avery AC, Breen M, Mason NJ, O'Brien TD, Modiano JF. 2012. CD40 ligand is necessary and sufficient to support primary diffuse large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies. Leuk. Lymphoma 53:1390–1398. http://dx.doi.org/10.3109/10428194.2011.654337.
   PubMed Web of Science ®Google Scholar
• Galan JA, Paris LL, Zhang H-J, Adler J, Geahlen RL, Tao WA. 2011. Proteomic studies of Syk-interacting proteins using a novel amine-specific isotope tag and GFP nanotrap. J. Am. Soc. Mass Spectrom. 22:319–328. http://dx.doi.org/10.1007/s13361-010-0030-7.
   PubMedGoogle Scholar
• Bachelor MA, Bowden GT. 2004. Ultraviolet A-induced modulation of Bcl-XL by p38 MAPK in human keratinocytes. Post-transcriptional regulation through the 3′-untranslated region. J. Biol. Chem. 279:42658–42668. http://dx.doi.org/10.1074/jbc.M406626200.
   PubMedGoogle Scholar
• Zhang J, Tsaprailis G, Bowden GT. 2008. Nucleolin stabilizes Bcl-XL messenger RNA in response to UVA irradiation. Cancer Res. 68:1046–1054. http://dx.doi.org/10.1158/0008-5472.CAN-07-1927.
   PubMedGoogle Scholar
• Schieven GL, Kirihara JM, Burg DL, Geahlen RL, Ledbetter JA. 1993. p72syk tyrosine kinase is activated by oxidizing conditions that induce lymphocyte tyrosine phosphorylation and Ca2+ signals. J. Biol. Chem. 268:16688–16692.
   PubMed Web of Science ®Google Scholar
• Xue L, Wang W-H, Iliuk A, Hu L, Galan JA, Yu S, Hans M, Geahlen RL, Tao WA. 2012. Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates. Proc. Natl. Acad. Sci. U. S. A. 109:5615–5620. http://dx.doi.org/10.1073/pnas.1119418109.
   PubMed Web of Science ®Google Scholar
• Keshvara LM, Isaacson C, Yankee TM, Sarac R, Harrison ML, Geahlen RL. 1998. Syk- and Lyn-dependent phosphorylation of Syk on multiple tyrosines following B-cell activation includes a site that negatively regulates signaling. J. Immunol. 161:5276–5283.
   PubMed Web of Science ®Google Scholar
• Yu S, Huang H, Iliuk A, Wang W-H, Jayasundera KB, Tao WA, Post CB, Geahlen RL. 2013. Syk inhibits the activity of protein kinase A by phosphorylating tyrosine 330 of the catalytic subunit. J. Biol. Chem. 288:10870–10881. http://dx.doi.org/10.1074/jbc.M112.426130.
   PubMedGoogle Scholar
• Minobe K, Onda M, Iida A, Kasumi F, Sakamoto G, Nakamura Y, Emi M. 1998. Allelic loss on chromosome 9q is associated with lymph node metastasis of primary breast cancer. Jpn. J. Cancer Res. 89:916–922. http://dx.doi.org/10.1111/j.1349-7006.1998.tb00649.x.
   PubMedGoogle Scholar
• Yuan Y, Mendez R, Sahin A, Dai JL. 2001. Hypermethylation leads to silencing of the SYK gene in human breast cancer. Cancer Res. 61:5558–5561.
   PubMed Web of Science ®Google Scholar
• Moroni M, Soldatenkov V, Zhang L, Zhang Y, Stoica G, Gehan E, Rashidi B, Singh B, Ozdemirli M, Mueller SC. 2004. Progressive loss of Syk and abnormal proliferation in breast cancer cells. Cancer Res. 64:7346–7354. http://dx.doi.org/10.1158/0008-5472.CAN-03-3520.
   PubMed Web of Science ®Google Scholar
• Hoeller C, Thallinger C, Pratscher B, Bister MD, Schicher N, Loewe R, Heere-Ress E, Roka F, Sexl V, Pehamberger H. 2005. The non-receptor-associated tyrosine kinase Syk is a regulator of metastatic behavior in human melanoma cells. J. Investig. Dermatol. 124:1293–1299. http://dx.doi.org/10.1111/j.0022-202X.2005.23685.x.
   PubMedGoogle Scholar
• Yuan Y, Wang J, Li J, Wang L, Li M, Yang Z, Zhang C, Dai JL. 2006. Frequent epigenetic inactivation of spleen tyrosine kinase gene in human hepatocellular carcinoma. Clin. Cancer Res. 12:6687–6695. http://dx.doi.org/10.1158/1078-0432.CCR-06-0921.
   PubMedGoogle Scholar
• Muthusamy V, Duraisamy S, Bradbury CM, Hobbs C, Curley DP, Nelson B, Bosenberg M. 2006. Epigenetic silencing of novel tumor suppressors in malignant melanoma. Cancer Res. 66:11187–11193. http://dx.doi.org/10.1158/0008-5472.CAN-06-1274.
   PubMed Web of Science ®Google Scholar
• Layton T, Stalens C, Gunderson F, Goodison S, Silletti S. 2009. Syk tyrosine kinase acts as a pancreatic adenocarcinoma tumor suppressor by regulating cellular growth and invasion. Am. J. Pathol. 175:2625–2636. http://dx.doi.org/10.2353/ajpath.2009.090543.
   PubMed Web of Science ®Google Scholar
• Yip KW, Reed JC. 2008. Bcl-2 family proteins and cancer. Oncogene 27:6398–6406. http://dx.doi.org/10.1038/onc.2008.307.
   PubMed Web of Science ®Google Scholar
• Kelly PN, Strasser A. 2011. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ. 18:1414–1424. http://dx.doi.org/10.1038/cdd.2011.17.
   PubMed Web of Science ®Google Scholar
• Lee YH, Mungunsukh O, Tutino RL, Marquez AP, Day RM. 2010. Angiotensin-II-induced apoptosis requires regulation of nucleolin and Bcl-xL by SHP-2 in primary lung endothelial cells. J. Cell Sci. 123:1634–1643. http://dx.doi.org/10.1242/jcs.063545.
   PubMedGoogle Scholar
• Mongelard F, Bouvet P. 2007. Nucleolin: a multifaceted protein. Trends Cell Biol. 17:80–88. http://dx.doi.org/10.1016/j.tcb.2006.11.010.
   PubMed Web of Science ®Google Scholar
• Srivastava M, Pollard HB. 1999. Molecular dissection of nucleolin's role in growth and cell proliferation: new insights. FASEB J. 13:1911–1922.
   PubMed Web of Science ®Google Scholar
• Groesch TD, Zhou F, Matilla S, Geahlen RL, Post CB. 2006. Structural basis for the requirement of two phosphotyrosine residues in signaling mediated by Syk tyrosine kinase. J. Mol. Biol. 356:1222–1236. http://dx.doi.org/10.1016/j.jmb.2005.11.095.
   PubMedGoogle Scholar
• Chen C-H, Martin VA, Gorenstein NM, Geahlen RL, Post CB. 2011. Two closely-spaced tyrosines regulate NFAT signaling in B cells via Syk association with Vav. Mol. Cell. Biol. 31:2984–2996. http://dx.doi.org/10.1128/MCB.05043-11.
   PubMedGoogle Scholar
• Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, Furlong MT, Geahlen RL, Tybulewicz VLJ. 1995. Perinatal lethality and a block in the development of B cells in mice lacking the tyrosine kinase p72syk. Nature 378:298–302. http://dx.doi.org/10.1038/378298a0.
   PubMed Web of Science ®Google Scholar
• Grillot DAM, Merino R, Pena JC, Fanslow WC, Finkelman FD, Thompson CB, Núñez G. 1996. bcl-x exhibits regulated expression during B cell development and activation and modulates lymphocyte survival in transgenic mice. J. Exp. Med. 183:381–391. http://dx.doi.org/10.1084/jem.183.2.381.
   PubMed Web of Science ®Google Scholar
• Tuscano JM, Druey KM, Riva A, Pena J, Thompson CB, Kehrl JH. 1996. Bcl-x rather than Bcl-2 mediates CD40-dependent centrocyte survival in the germinal center. Blood 88:1359–1364.
   PubMed Web of Science ®Google Scholar